Astria Therapeutics, Inc.
CIK 0001454789
Revenue (TTM)
—
Q3 Oct 2025
Net Income (TTM)
−$122.94M
−29.3% YoY
Q3 Oct 2025
EPS Diluted (TTM)
−$2.12
+30.6% YoY
Q3 Oct 2025
Gross Margin
—
Q3 Oct 2025
Operating Margin
—
Q3 Oct 2025
Net Margin
—
Q3 Oct 2025
Free Cash Flow (TTM)
−$79.25M
Q3 Oct 2025
Cash
$96.28M
Q3 Oct 2025
Total Debt
$1.66M
Q3 Oct 2025
Shares Outstanding
57.08M sh
Q3 Oct 2025
Revenue & Net Income
EPS (Diluted)
Cash Flow
Revenue Growth (YoY)
No data available for this metric.